| CAS NO: | 6055-19-2 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 50mg | 电议 |
| 5g | 电议 |
| 10g | 电议 |
| Cas No. | 6055-19-2 |
| 别名 | 环磷酰胺水合物; Cyclophosphamide monohydrate |
| 化学名 | N,N-bis(2-chloroethyl)-2-oxo-1,3,2λ5-oxazaphosphinan-2-amine;hydrate |
| Canonical SMILES | C1CNP(=O)(OC1)N(CCCl)CCCl.O |
| 分子式 | C7H15Cl2N2O2P.H2O |
| 分子量 | 279.1 |
| 溶解度 | ≥ 13.95 mg/mL in DMSO, ≥ 96 mg/mL in EtOH, ≥ 51.5 mg/mL in Water with ultrasonic and warming |
| 储存条件 | Store at -20°C,unstable in solution, ready to use. |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | IC50: 511 μM for AChE Cyclophosphamide monohydrate is used in the cancer treatment in children. As a prodrug it should be metabolized by cytochrome P-450 enzymes to produce the active alkylating species, which are responsible for its cytotoxic effects. In vitro: Cyclophosphamide inhibited the AChE reversibly with an IC50 of 511 μM. In the control system, Km was 132 μM for AChE, which increased by 78% in the CP treated system. The nature of cyclophosphamide was of the linear mixed type (partially competitive and purely noncompetitive). The values of Ki and KI were estimated to be 378 and 582 μM respectively, indicating that noncompetitive inhibition was predominant over competitive [1]. In vivo: PK studies in mice revealed a delayed plasma clearance of cyclophosphamide after carbon-tetrachloride pretreatment. Plasma levels of total alkylating activity and 4-hydroxycyclophosphamide increased more slowly and reached a lower peak. However, there was no difference in the AUC for either plasma total alkylating activity or plasma 4-hydroxycyclophosphamide between two groups. Thus, prolonged exposure of tumor cells to 4-hydroxycyclophosphamide might be responsible for the increased antitumor activity of cyclophosphamide following carbon-tetrachloride pretreatment [2]. Clinical trial: Twenty-two children not receiving other therapy known to influence drug metabolism were selected, of whom, nine were receiving combination treatment and thirteen were identified as controls. Results showed that the the plasma cyclophosphamide clearance was lower in patients receiving fluconazole combined group [3]. References: |
m.cnreagent.com